A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With Fibromyalgia
Phase of Trial: Phase III
Latest Information Update: 28 Sep 2016
At a glance
- Drugs Cyclobenzaprine (Primary)
- Indications Fibromyalgia; Myofascial pain
- Focus Therapeutic Use
- Acronyms RE-AFFIRM
- Sponsors Tonix Pharmaceuticals Holding Corp
- 19 Sep 2016 Status changed from recruiting to discontinued.
- 26 Jul 2016 According to a Tonix Pharmaceuticals Holding Corp media release, first patient has been randomized in this study.
- 20 Jul 2016 Status changed from not yet recruiting to recruiting.